Atlas Trials

First in Human Study to Evaluate the Safety and Tolerability of GEM103 in Geographic Atrophy Secondary to Dry Age Related Macular Degeneration

Clinical trial NCT04246866 · COMPLETED

Trial details

NCT number
NCT04246866
Sponsor
Gemini Therapeutics, Inc.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Dry Age-related Macular DegenerationGeographic AtrophyMacular DegenerationRetinal DiseaseRetinal Degeneration
Start date
2019-12-19
Primary completion
2020-10-21
Enrollment
12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.